Show simple item record

dc.contributor.authorFernandes, Leticia Aparecida Barufipt_BR
dc.contributor.authorCestario, Elizabeth do Espirito Santopt_BR
dc.contributor.authorCosenso-Martin, Luciana Nevespt_BR
dc.contributor.authorMartin, Jose Fernando Vilelapt_BR
dc.contributor.authorYugar-Toledo, Juan Carlospt_BR
dc.contributor.authorFuchs, Flávio Dannipt_BR
dc.date.accessioned2021-08-31T04:21:03Zpt_BR
dc.date.issued2016pt_BR
dc.identifier.issn1923-2829pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/226317pt_BR
dc.description.abstractBackground: Hypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure. Related clinical implications suggest that individuals with normal peripheral but high central blood pressure should not receive antihypertensive drugs that act on the central pressure. Therefore, they are at greater cardiovascular risk. The aim of the study was to evaluate the effect of treatment with a thiazide diuretic versus losartan on the central blood pressure in stage 1 hypertensive patients. Methods: Twenty-five patients were randomized to the chlorthalidone 25 mg/amiloride 5 mg group (q.d.) and 25 patients received losartan 50 mg (b.i.d). The central systolic blood pressure (CSBP) and augmentation index (AIx 75) were assessed using applanation tonometry. The paired t-test was used to compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), CSBP and AIx 75 between the thiazide and losartan groups at baseline and after 6 months of treatment. Results: Significant reductions in CSBP (123.3 ± 14.2 vs. 113.4 ± 111.4, P = 0.0103) and AIx 75 (87.7 ± 9.6 vs. 83.8 ± 8.9, P = 0.0289) were observed after 6 months of drug treatment with chlorthalidone 25 mg/amiloride 5 mg (q.d.). The administration of losartan 50 mg (b.i.d) did not reduce the CSBP and there were insignificant changes in the AIx 75. Conclusions: Six-month treatment of chlorthalidone/amiloride but not losartan reduces the CSBP and AIx 75 in adults with stage 1 hypertension.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofCardiology research. Quebec. Vol. 7, no. 6 (2016), p. 196-201.pt_BR
dc.rightsOpen Accessen
dc.subjectPressão sanguíneapt_BR
dc.subjectStage 1 hypertensionen
dc.subjectCentral systolic blood pressureen
dc.subjectHipertensãopt_BR
dc.subjectChlorthalidoneen
dc.subjectClortalidonapt_BR
dc.subjectAmiloridapt_BR
dc.subjectAmilorideen
dc.subjectLosartanpt_BR
dc.subjectLosartanen
dc.titleChlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patientspt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001130052pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record